Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.97 |
| ▸ | HTR1A | P08908 | 5/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HTR1D | P28221 | 5/20 | 0.66 |
| ▸ | HTR1B | P28222 | 5/20 | 0.66 |
| ▸ | HTR7 | P34969 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733997 | 0.99 | MPO (1.00) | MPOHTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL26508398 | 0.96 | MPO (0.94) | MPOHTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL27836200 | 0.88 | MPO (1.00) | MPOHTR1AHTR1DHTR1BHTR7 | |
| SCHEMBL27836191 | 0.86 | MPO (0.78) | MPOHTR1AHTR1DHTR1BHTR7 | |
| SCHEMBL9541243 | 0.85 | MPO (0.76) | MPOHTR1AHTR7 | |
| SCHEMBL26508393 | 0.84 | MPO (0.75) | MPOHTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL5170221 | 0.84 | MPO (0.77) | MPOHTR1AHTR2A | |
| SCHEMBL26989598 | 0.83 | HTR7 (0.70) | MPOHTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL8557700 | 0.82 | MPO (0.71) | MPOHTR1AHTR2AHTR7 | |
| SCHEMBL6969548 | 0.82 | HTR1D (0.73) | MPOHTR2AHTR1DHTR1BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | MPO 4308/4885HTR1A 746/4885HTR2A 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.